# Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-26-313-single-source-for-continuation-of-the-accelerating-medicines/  
Official notice: https://www.grants.gov/search-results-detail/359015

> National Institutes of Health offered grants of up to $2.0 million to the applicants described in the notice. It expected to make one award. Applications closed on March 10, 2026.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-26-313 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | March 10, 2026 |
| Award ceiling | $2.0 million |
| Award floor | not stated |
| Expected awards | 1 |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Only the following applicant is eligible to apply for this single source funding: The Broad Institute, Inc. Please refer to Section I. Notice of Funding Opportunity Information for more details.

## What the grant funds

This non-competitive Notice of Funding Opportunity (NOFO) is intended to fund a single award to the current awardee institution of the Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP), the Broad Institute, Inc. The AMP CMD program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time NOFO to provide funds to the AMP CMD KP to continue the development and maintenance of the web portal and underlying, curated knowledge base; which serves as the flagship resource encompassing the myriad types of data and information that provide an understanding of the biological heterogeneity in patients with CMDs and their related complications. In its next five-year period, the AMP CMD KP will be expected to continue its expansion of its datasets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base, and to develop a framework for independent sustainability. The application will be peer-reviewed and if it is not a meritorious application, it will not be funded.

## Questions people ask

### Is RFA-DK-26-313 still open?

No. It closed on March 10, 2026.

### Who can apply for Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed)?

National Institutes of Health accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed)?

Closed March 10, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $2.0 million each.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.